Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Lower treatment odds for women were also observed in a set of 7 studies that had data on the subgroup of patients eligible for IV rtPA treatment.
Matthew Reeves, PhD, BVSc
The treatment gap in intravenous (IV) thrombolysis has narrowed between men and women with stroke since 2008, according to a new meta-analysis.
Despite considerable variability in the findings of individual studies, the recently pooled data showed that women with acute stroke were still less likely to be treated with IV thrombolysis.
However, pooled data from 2000-2008 suggest that women were 30% less likely to receive recombinant tissue plasminogen activator (rtPA) therapy, while this analysis of data from 2008-2018 suggest that gap has narrowed to 13% less likely.
The summary unadjusted odds ratio (OR) based on those 17 studies with data on all time points was 0.87 (95% CI, 0.82—0.93).
When directly comparing summary ORs, the group determined that women’s odds of receiving treatment were significantly different between 2000 to 2004 (OR, 0.73; 95% CI, 0.67—0.80) and between 2014-2018 (OR, 0.9; 95% CI, 0.84–0.97).
The data were compiled by a trio of authors including Mathew Reeves, PhD, BVSc, professor of epidemiology and biostatistics, Michigan State University, and colleagues, and included 24 eligible studies which had representative populations of patients with ischemic stroke from hospital-based, registry-based, or administrative data; there were 33 total studies included in the categorization of 4 time periods.
“We are heartened that this treatment gap has narrowed, but more research is definitely needed into why a gap persists and whether it is continuing to get smaller,” Reeves said in a statement. “This is especially important as additional treatments for acute stroke are developed and implemented.”
Lower treatment odds for women were also observed in a set of 7 studies that had data on the subgroup of patients eligible for IV rtPA treatment, although the summary OR of 0.95 (95% CI, 0.88—1.02) was not statistically significant.
Reeves did note that when observing the hard numbers, the absolute difference in treatment rates between men and women was modest.
"Most of the studies showed differences of 0.5% to 1.0%," he said. "The largest difference in one study was 8.4%. Still, even small differences could translate into many untreated women given how common stroke is in the elderly population. These missed opportunities have greater consequences for women since they tend to have more serious disability and are more likely to die after a stroke than men, but importantly, have been shown to benefit just as much from treatment as men do.”
The investigators did acknowledge that these differences may be, in part, due to the likelihood of women to live alone compared to men, which might result in a later presentation to the hospital or lack of awareness of symptom onset.
Additionally, stroke in women can present with atypical symptoms, making diagnosis more complex or time-consuming.
Women, Reeves noted, may be more likely to have non-traditional stroke symptoms such as a loss of alertness, weakness, or incontinence.
"Clot-busting treatments must be given within a few hours of when the stroke occurred to be effective, so delays will make people ineligible for treatment," he said in a statement.